The fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.
KraneShares MSCI All China Health Care Index ETF · Issued by KraneShares
| 1801.HK | Innovent Biologics Inc | 9.39% |
| 6160.HK | BeOne Medicines Ltd Ordinary Shares | 8.75% |
| 2269.HK | WuXi Biologics (Cayman) Inc | 7.29% |
| 603259.SS | Wuxi AppTec Co Ltd Class A | 5.46% |
| 300760.SZ | Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A | 4.63% |
| 1177.HK | Sino Biopharmaceutical Ltd | 3.79% |
| 600276.SS | Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 3.63% |
| 1093.HK | CSPC Pharmaceutical Group Ltd | 3.59% |
| 9926.HK | Akeso Inc Ordinary Shares | 3.54% |
| 02359 | Wuxi AppTec Co Ltd | 3.17% |
No recent news for KURE. The ingest cron pulls every 15 minutes during market hours.